CYP (ASX) CYP BTFD

Originally posted by ashc36 ↑

In my opinion as a long term holder i think management made the right call with the cap raise.
The fuji announcement was not what i was expecting. I was expecting an upfront payment with milestone payments and royalties, not an option to get this based on safety of the upcoming trial. It appears no one will sign until safety of the our cells is proven in humans. This is fair enough i guess as well as i would not pay upfront fee for a product that may not work.

With this mind the price after the fuji announcement may have got up to the 90's early but i have no doubt would fallen to low seventies soon after. It would have fallen even lower after as the market digests the news that no big deal will happen until safety proved. With no big news on the horizon and apceth taking their time, management decided to raise 6 million whilst momentun was good. I think this was smart as it may be until mid 2018 until fuji decide to take up their option with safety proven. Apceth will likely not sign until safety is proven either. 8 million in cash (fuji $4, existing 4) may not have lasted til then. It certainly would not leave much fat for work in other areas like heart attack and brain cancer. These are worth pursuing. A patient Paying around 20k to help treat brain cancer or reduce risk of a heart attack for those high at risk seems like a no brainer. 20k for treatment for asthma suffers that can use a cheap inhaler instead seems a bit inpractible. We cant rely on others to help fund this research when it seems obvious that they want safety proven. Not doing a cap raise would leave us with up to 1 and half years with no further work in these areas. Now that would be a dumb move. When safety is proven these areas will be ready for a deal in 2018 with more studies.

Thankfully the safety trial is this year. Boom or bust. Knew that coming in though. Recruitment may take to the middle of the year so im not expecting any announcement soon. The condition is quite rare so patience is required. Once the trial starts though results will be fairly quick. We may not get the official results for quite some time after as much analysis needs to be done but from other shares history the market price movement will likely indicate what they are. When the trial starts i expect plenty of interest as positive data will mean lots of deals. We should hopefully get back to $1 at least upon trial commencement. Safety data will i think will highly likely will be good based on the animal data so far but stranger things have occurred.

Technically it looks like 50 cents will be the next stop. There should be plenty of support here. Fuji paid about this. Fuji would not have forked out 3million usd and spent countless man hours on the option agreement if they did not think it would be worth it. They have done a stack of due dillengence. If its good enough for them it should be at least good enough for the market. Hopefully should rise from there.

Expand

My concern is CR was such low ball that suggested to market Pre ANN share price very overvalued. The change in sentiment became self fulfilling and set in motion major technical correction.

I agree with logic in raising money for lean period ahead but agree with point others make that company fail to explain to market how capital will be use to accelerate R&D timelines.

All tactical errors by company. Research team can have long term and visionary focus but company executives must try harder to make smooth and comfortable daily journey for investors

No.	Vol.	Price($)
1	62856	26.0¢

No.

Vol.

Price($)

62856

26.0¢

Price($)	Vol.	No.
27.0¢	30000	1

Price($)

Vol.

No.

27.0¢

30000

No.	Vol.	Price($)
1	62856	0.260
1	34500	0.255
1	27654	0.250
2	26342	0.245
3	104100	0.240

No.

Vol.

Price($)

62856

0.260

34500

0.255

27654

0.250

26342

0.245

104100

0.240

Price($)	Vol.	No.
0.270	30000	1
0.280	3000	1
0.290	4125	2
0.295	183892	1
0.300	85000	2

Price($)

Vol.

No.

0.270

30000

0.280

3000

0.290

4125

0.295

183892

0.300

85000

(20min delay)
Last 26.0¢		Change 0.005(1.96%)		Mkt cap ! $46.70M

Open	High	Low	Value	Volume
25.5¢	26.0¢	25.5¢	$2.003K	7.837K

CYP BTFD, page-19

Evolution shares up 3% on quarterly results for June showing rise in gold production

AI stocks: What to expect in 2024-25

Andrew Forrest was seemingly possessed by the spirit of hydrogen – now he's cut 700 jobs and canned FFI

Noronex joins forces with South32 to look for copper in Namibia

Talking Australia's very competitive property landscape: Realty Talks

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

CYP BTFD, page-19

Top Stories

Evolution shares up 3% on quarterly results for June showing rise in gold production

AI stocks: What to expect in 2024-25

Andrew Forrest was seemingly possessed by the spirit of hydrogen – now he's cut 700 jobs and canned FFI

Noronex joins forces with South32 to look for copper in Namibia

Talking Australia's very competitive property landscape: Realty Talks

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News